Edgen Stock·Sep 29 2025, 18:59戻る
戻る
Olanzapine LAI Demonstrates Favorable Safety Profile in Phase 3 Trial, Bolstering Medincell and Teva Prospects
Edgen Stock·Sep 29 2025, 18:59
[1] Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile – No PDSS Observed[2] Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed[3] Medincell's Olanzapine LAI: A New Benchmark in Schizophrenia Treatment Safety and Efficacy - AInvest